Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CTRO-2018
- Development stage
- Preclinical
- Lead developer
- insitro
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
CTRO-2018 is an oligonucleotide therapeutic currently in the molecule design phase for the treatment of amyotrophic lateral sclerosis (ALS). Developed by insitro in collaboration with Bristol Myers Squibb, the program was identified using insitro's machine learning-enabled Virtual Human platform, which models disease phenotypes in patient-derived induced pluripotent stem cells (iPSCs) to discover novel therapeutic targets.
- Other names
- CTRO 2018CTRO2018CTRO-2018
Beyond the preview
Go deeper on CTRO-2018.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CTRO-2018.